Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Sales (2016 - 2025)

Historic Return on Sales for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 0.13%.

  • Myriad Genetics' Return on Sales fell 300.0% to 0.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.49%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 0.15% for FY2024, which is 2000.0% up from last year.
  • Per Myriad Genetics' latest filing, its Return on Sales stood at 0.13% for Q3 2025, which was down 300.0% from 1.55% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Return on Sales registered a high of 0.15% during Q3 2021, and its lowest value of 1.55% during Q2 2025.
  • For the 5-year period, Myriad Genetics' Return on Sales averaged around 0.24%, with its median value being 0.16% (2023).
  • As far as peak fluctuations go, Myriad Genetics' Return on Sales skyrocketed by 5700bps in 2021, and later plummeted by -13800bps in 2025.
  • Myriad Genetics' Return on Sales (Quarter) stood at 0.05% in 2021, then plummeted by -403bps to 0.24% in 2022, then surged by 33bps to 0.16% in 2023, then dropped by -27bps to 0.2% in 2024, then soared by 34bps to 0.13% in 2025.
  • Its Return on Sales stands at 0.13% for Q3 2025, versus 1.55% for Q2 2025 and 0.0% for Q1 2025.